ANI Pharmaceuticals, Inc. (ANIP)
Market Cap | 1.17B |
Revenue (ttm) | 674.07M |
Net Income (ttm) | -22.43M |
Shares Out | 20.02M |
EPS (ttm) | -1.15 |
PE Ratio | n/a |
Forward PE | 9.18 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 218,789 |
Open | 58.26 |
Previous Close | 57.81 |
Day's Range | 57.41 - 58.37 |
52-Week Range | 52.50 - 77.00 |
Beta | 0.56 |
Analysts | Strong Buy |
Price Target | 80.13 (+37.92%) |
Earnings Date | May 9, 2025 |
About ANIP
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chains, distributors and specialty pharmacies, group pu... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for ANIP stock is "Strong Buy." The 12-month stock price forecast is $80.13, which is an increase of 37.92% from the latest price.
News

ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
PRINCETON, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2025 J...

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares
Purified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of acute gout flares Trial to be conducted by Dr. Hyon Choi at Massachusetts General Hospital and will compare t...

ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ
PRINCETON, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief F...

ANI Pharmaceuticals, Inc. (ANIP) Q1 2025 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2025 Earnings Conference Call May 9, 2025 8:00 AM ET Company Participants Lisa Wilson - IR, Insight Communications Nikhil Lalwani - President, CEO & Directo...

ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance
BAUDETTE, Minn., May 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the first quarter ended Ma...

ANI Pharmaceuticals: A Short-Term Buying Opportunity
ANIP is expected to raise 2025 guidance due to FDA approval and launch of TEZRULY and INZIRQO, addressing unmet needs for dysphagic patients. Both drugs are patent protected until 2042 and offer new f...

ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis (EAU) Mouse Model
Demonstrated Dose Dependent Effect in EAU Presented in a podium presentation at The Association for Research in Vision and Ophthalmology (ARVO) 2025 annual meeting PRINCETON, N.J., May 05, 2025 (GLOBE...

ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET
PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2025 financial res...

ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference
PRINCETON, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, will h...

ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets
PRINCETON, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Nitazoxanide Tablets, 500 mg. ANI's Nitazoxanide Tablets...

ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ®
BAUDETTE, Minn., March 18, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed the buyout of its 3.125% perpetual royalty oblig...

ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label
BAUDETTE, Minn., March 14, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the U.S. Food and Drug Administration (FDA) has approved an expan...

ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe
PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA) approval of Purified Cortrophi...

ANI Pharmaceuticals, Inc. (ANIP) Q4 2024 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2024 Earnings Conference Call February 28, 2025 8:00 AM ET Company Participants Lisa Wilson - IR, Insight Communications Nikhil Lalwani - President, CEO & D...

ANI Pharmaceuticals Expects Strong Start To 2025, On Back Of Cortrophin Gel And Generics, Lifts Annual Forecast
On Friday, ANI Pharmaceuticals Inc ANIP reported fourth-quarter adjusted EPS of $1.63, up from $1 a year ago, beating the consensus of $1.44.

ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance
BAUDETTE, Minn., Feb. 28, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the fourth quarter and f...

ANI Pharmaceuticals to Present at Raymond James' Institutional Investors and Leerink Partners Global Healthcare Conferences in March
PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and sel...

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET
PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2024...

ANI Pharmaceuticals: More Than Just A Generics Company
ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, and contract manufacturing. Despite cash burn concerns, ANI's revenue growt...

ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference
PRINCETON, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Ste...

Alcami Announces CEO Transition
Long time industry leader, Chairman of the Board Patrick Walsh replaces CEO Bill Humphries DURHAM, N.C. , Jan. 13, 2025 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development ...

ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook
BAUDETTE, Minn., Jan. 13, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today affirmed its prior net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP ...

ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity
PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administratio...

ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PRINCETON, N.J., Dec. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer; Stephen...